Two Akero employees seated and talking at a conference room table

Our Clinical Trials

Our comprehensive clinical development program is designed to evaluate the safety and efficacy of EFX in people with MASH.

Our ongoing Phase 3 SYNCHRONY program is evaluating EFX for the treatment of MASH with moderate to advanced (F2/F3) or compensated cirrhosis (F4c). The SYNCHRONY clinical trials are based on results from our Phase 2 program and were designed in consultation with global regulatory authorities.

Table illustrating the status, endpoints, treatment duration, and doses in Akero’s clinical trials

SYNCHRONY

STATUS: ongoing
The Phase 3 SYNCHRONY clinical trial program consists of three randomized, placebo-controlled trials:
  • SYNCHRONY Histology is evaluating the efficacy and safety of EFX in patients with biopsy-defined noncirrhotic MASH and moderate to advanced fibrosis (F2/F3);
  • SYNCHRONY Real-World is evaluating the efficacy and safety of EFX in people with noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD) and mild to advanced fibrosis (F1-F4);
  • SYNCHRONY Outcomes is evaluating the efficacy and safety of EFX in people with MASH cirrhosis.
Study details are available at ClinicalTrials.gov: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. Learn more about enrolling in the SYNCHRONY Histology clinical trial.
Close up of multichannel micropipette filling four small blue centrifuge tubes

Interested in participating in one of our clinical studies?

Information for Patients